Amalgamated Financial’s Fate Therapeutics FATE Stock Holding History

Amalgamated Financial’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$515K	Buy	+13,286	New	+$514K	﹤0.01%	1502

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Amalgamated Financial's FATE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Fate Therapeutics (FATE) in Q1 2022: 13,286 shares worth $515K. The stake represents ﹤0.01% of the portfolio and ranks #1502 among its holdings.

250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

Amalgamated Financial held 13,286 shares of Fate Therapeutics worth $515K as of Q1 2022.
Fate Therapeutics was a new Amalgamated Financial position in Q1 2022.
Fate Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1502 holding.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.